Herbs (Global Traditional) · Siddha
Nilavembu Kudineer (Andrographis paniculata) (Andrographis paniculata)
Strong Evidencebotanical
Hermetica Superfood Encyclopedia
Nilavembu Kudineer is a traditional Siddha medicine preparation containing Andrographis paniculata that demonstrates antimicrobial and anti-inflammatory properties through its primary bioactive compound andrographolide. This polyherbal formulation works by inhibiting inflammatory pathways and showing potential antiviral activity against respiratory pathogens.
Nilavembu Kudineer is a polyherbal Siddha medicine formulation comprising nine plant ingredients in equal proportions, with Andrographis paniculata (King of Bitters) as the chief component. The formulation is prepared by drying and powdering equal parts of nine medicinal plants, traditionally used in Siddha medicine, one of India's classical traditional medicine systems.
The available research consists primarily of computational and mechanistic studies rather than human clinical trials. No randomized controlled trials or meta-analyses with PubMed PMIDs were found in the provided research dossier. The evidence base consists of in silico modeling showing potential SARS-CoV-2 spike protein binding and molecular mechanism studies identifying 32 bioactive compounds.
No clinically studied dosage ranges were specified in the research. The formulation is available in coarsely powdered form, but standardized dosing protocols and standardization parameters are not detailed in the available sources. Consult a healthcare provider before starting any new supplement.
Andrographolide, the primary diterpenoid in Nilavembu Kudineer, inhibits nuclear factor-kappa B (NF-κB) signaling pathways, reducing pro-inflammatory cytokine production. The compound also demonstrates potential viral spike protein binding affinity through computational studies. Additional bioactive compounds like β-vetiverine and α-zingiberene contribute to broad-spectrum antimicrobial activity.
Current evidence for Nilavembu Kudineer is primarily based on computational studies and traditional use documentation rather than large-scale human clinical trials. In silico studies suggest potential antiviral activity against SARS-CoV-2 spike proteins, while laboratory studies confirm antimicrobial properties of isolated compounds. The Tamil Nadu government distributed this formulation during COVID-19 as a preventive measure based on traditional use, but robust randomized controlled trials with quantified clinical outcomes remain limited.
Nilavembu Kudineer is generally well-tolerated based on traditional use patterns, though comprehensive safety data from controlled studies is lacking. The preparation may interact with medications metabolized by liver enzymes due to andrographolide's hepatic effects. Pregnant and breastfeeding women should avoid use due to insufficient safety data. Individuals with autoimmune conditions should exercise caution as the formulation may modulate immune system activity.
